Pioglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, is currently under investigation in a Phase II placebo-controlled clinical trial for the treatment of early PD. This evidence concerns the gene PPARG and Parkinson disease.